Psychedelics Industry Scores Reform Wins in Oregon and DC

- November 4th, 2020

During a long night of election coverage and results, psychedelics legalization measures cleared in two states.

The psychedelics market received votes of confidence from Oregon and Washington, DC, as new reforms were approved to boost legalization efforts.

In Oregon, voters approved a measure seeking to legalize psilocybin mushrooms for controlled therapeutic use, while the US capital voted in favor of a policy to decriminalize psychedelic substances in the form of certain psychedelic plants and fungi.

Both ballot results were confirmed by Marijuana Moment after projections from the Associated Press.

 

New FREE Report: Investing in Psychedelics

   
What’s ahead for this exciting new segment? Learn more with our exclusive psychedelics report today.
 

The psilocybin measure won’t allow for the sale of psilocybin over the counter or of branded products, but instead will allow those 21 or older to gain access to supervised spaces for the administration of psilocybin for general therapeutic causes.

In a statement, the campaign behind the measure thanked all its supporters and those that helped get the policy across the finish line.

“Healthcare professionals, veterans, mothers, people struggling with depression, anxiety, addiction and end of life distress, community organizations, and so many others answered to call for a new option to help so many who are suffering,” the group said.

Melissa Lavasani, who introduced the DC measure, described the positive vote as a win that indicates public perception of psychedelics is changing.

“We have changed the game here. We have shifted this dialogue,” she said, according to a report from the Washington Post. “We are trying to normalize mental health.”

Overall, 2020 has been a critical year for the psychedelics industry as a whole thanks to the arrival of more mainstream stocks and growing interest in from the wider capital markets. Momentum is picking up for the sector, according to experts.

An index tracking just over 30 stocks in the psychedelics space was up nearly 10 percent in Wednesday’s (November 4) trading session, showing some of the immediate investment activity.

Industry standard bearers like Compass Pathways (NASDAQ:CMPS) and Mind Medicine (MindMed) (NEO:MMED,OTCQB:MMEDF) were also both up near the end of the trading day.

As of 2:15 p.m. EST, Compass shares were up 9.85 percent for a price tag of US$36.24, while MindMed was enjoying an increase in value of 5.5 percent for a price per share of C$1.15.

Don’t forget to follow us @INN_LifeScience for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

  Life Science and Healthcare Investing in 2020 report cover

Coronavirus Investing: An Overview for Investors

 
COVID-19 continues to impact markets across the world. Get INN’s overview of coronavirus investing.
 

Get the latest Psychedelics Investing stock information

Get the latest information about companies associated with Psychedelics Investing Delivered directly to your inbox.

Psychedelics Investing

Select None
Select All

Leave a Reply